A study investigating the effect of adding bleximenib to standard treatment with intensive chemotherapy in patients with a specific form of acute myeloid leukemia (AML)
The treatment of adult patients with acute myeloid leukemia (AML) must be further improved. The current standard of care consists of chemotherapy and, if indicated, a stem cell transplant from a donor. However, the disease remains incurable for a significant number of patients. Bleximenib is a new drug that blocks the interaction between a protein called menin and other proteins in leukemia cells. When this interaction is disrupted by bleximenib, the leukemia cells are killed.
The primary objective is to assess whether treatment with bleximenib, when administered in addition to standard therapy, improves treatment outcomes in adult patients with newly diagnosed AML and mutations in the NPM1 or KMT2A genes.
This is a randomized, double-blind, placebo-controlled Phase III clinical trial.
The study will enroll 875 previously untreated patients with AML who have a specific alteration in the DNA of their leukemia cells (a KMT2A rearrangement or an NPM1 mutation).
Participants will be assigned to one of three treatment groups:
- Group 1: Standard treatment plus bleximenib and maintenance treatment with bleximenib
- Group 2: Standard treatment plus bleximenib and maintenance treatment with a placebo
- Group 3: Standard treatment plus a placebo and maintenance treatment with a placebo
After completion of treatment in accordance with the study protocol, a 4-year follow-up period will begin from the date of enrollment of the last patient for the purpose of monitoring. The results of the various treatment groups will be compared.
Intervention Studied
Depending on the randomization result, participants will receive standard intravenous chemotherapy with (Treatment Group 1) or without bleximenib (Treatment Group 3), and the outcomes of these patient groups will be compared. Depending on the risk assessment, standard treatment may also include a stem cell transplant from a donor. In this study, a maintenance treatment period is added to the initial treatment plan. During maintenance therapy, patients will receive either bleximenib or a placebo. This is done to gain insight into the potential benefits of prolonged use of bleximenib (comparison of outcomes in treatment groups 1 and 2).
During the study, most (diagnostic) tests are part of standard care. However, during maintenance therapy, a maximum of 8 additional bone marrow tests will be performed. When standard bone marrow tests are performed, additional bone marrow will be collected for the study. Additional blood is also collected when blood is drawn as part of the standard procedure anyway.
Inclusion Criteria
- 18 years of age or older with newly diagnosed AML with a mutation in NPM1 or KMT2A and deemed eligible for intensive chemotherapy
- WHO/ECOG performance status ≤ 2
- Adequate renal and hepatic function prior to randomization
Exclusion Criteria
- Previous (chemotherapy) treatment for AML
- Known active leukemic involvement of the central nervous system
- Heart disease or chronic respiratory disease requiring supplemental oxygen
Hospitals
-
HFR Freiburg - Kantonsspital
-
HOCH Health Ostschweiz - Kantonsspital St. Gallen
-
Inselspital - Universitätsspital Bern
-
Kantonsspital Aarau AG
-
Les hôpitaux universitaires de Genève
-
Universitätsspital Basel
-
USZ Universitätsspital Zürich